safe nanocarriers? Critical Reviews in Toxicology 50 (2): 148–176. https://doi.org/10.1080/10408444.2020.1719974.4 Bayda, S., Adeel, M., Tuccinardi, T. et al. (2020). The history of nanoscience and nanotechnology: from chemical‐physical applications to nanomedicine. Molecules 25 (1): 1–15. https://doi.org/10.3390/molecules25010112.
5 Bobo, D., Robinson, K., Islam, J. et al. (2016). Nanoparticle‐based medicines: a review of FDA‐approved materials and clinical trials to date. Pharmaceutical Research 33 (10): 2373–2387. https://doi.org/10.1007/s11095‐016‐1958‐5.
6 Buzea, C. and Pacheco, I. (2017). Nanomaterials and their classification. In: EMR/ESR/EPR Spectroscopy for Characterization of Nanomaterials (ed. A. Shukla), 3–45. Springer (India) Pvt. Ltd.
7 Caster, J., Patel, A., Zhang, T., and Wang, A. (2017). Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology 9 (1): e1416. https://doi.org/10.1002/wnan.1416.
8 Chavan, T., Muttil, P., and Kunda, N. (2020). Introduction to Nanomedicine in Drug Delivery. Switzerland AG: Springer Nature.
9 Choi, Y. and Han, H. (2018). Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. Journal of Pharmaceutical Investigation 48 (1): 43–60. https://doi.org/10.1007/s40005‐017‐0370‐4.
10 Choi, Y., Lee, M., David, A., and Park, Y. (2014). Nanoparticles for gene delivery: therapeutic and toxic effects. Molecular & Cellular Toxicology 10 (1): 1–8. https://doi.org/10.1007/s13273‐014‐0001‐3.
11 De Jong, W. and Borm, P. (2008). Drug delivery and nanoparticles: applications and hazards. International Journal of Nanomedicine 3 (2): 133–149.
12 Dickinson, A., Godden, J., Lanovyk, K., and Ahmed, S. (2019). Assessing the safety of nanomedicines: a mini review. Applied In Vitro Toxicology 5 (3): 114–122. https://doi.org/10.1089/aivt.2019.0009.
13 El‐Ansary, A. and Al‐Daihan, S. (2009). On the toxicity of therapeutically used nanoparticles: an overview. Journal of Toxicology 2009: 1–9. https://doi.org/10.1155/2009/754810.
14 Eloy, J., Claro de Souza, M., Petrilli, R. et al. (2014). Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids and Surfaces B: Biointerfaces 123: 345–363. https://doi.org/10.1016/j.colsurfb.2014.09.029.
15 Fadeel, B. and Alexiou, C. (2020). Brave new world revisited: focus on nanomedicine. Biochemical and Biophysical Research Communications 533 (1): 36–49. https://doi.org/10.1016/j.bbrc.2020.08.046.
16 Fadeel, B., Kagan, V., Krug, H. et al. (2007). There's plenty of room at the forum: potential risks and safety assessment of engineered nanomaterials. Nanotoxicology 1 (2): 73–84. https://doi.org/10.1080/17435390701565578.
17 Farjadian, F., Ghasemi, A., Gohari, O. et al. (2019). Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (London) 14 (1): 93–126. https://doi.org/10.2217/nnm‐2018‐0120.
18 Fubini, B., Ghiazza, M., and Fenoglio, I. (2010). Physico‐chemical features of engineered nanoparticles relevant to their toxicity. Nanotoxicology 4: 347–363. https://doi.org/10.3109/17435390.2010.509519.
19 Gabizon, A., Catane, R., Uziely, B. et al. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene‐glycol coated liposomes. Cancer Research 54 (4): 987–992.
20 Gabizon, A., de Rosales, R., and La‐Beck, N. (2020). Translational considerations in nanomedicine: the oncology perspective. Advanced Drug Delivery Reviews 158: 140–157. https://doi.org/10.1016/j.addr.2020.05.012.
21 Gatoo, M., Naseem, S., Arfat, M. et al. (2014). Physicochemical properties of nanomaterials: implication in associated toxic manifestations. BioMed Research International 2014: 1–8. https://doi.org/10.1155/2014/498420.
22 Gaur, N., Sharma, N., Dahiya, A. et al. (2020). Toxicity and Regulatory Concerns for Nanoformulations in Medicine. Beverly, MA: Scrivener Publishing LLC.
23 George, S., Ho, S., Wong, E. et al. (2015). The multi‐facets of sustainable nanotechnology ‐ lessons from a nanosafety symposium. Nanotoxicology 9 (3): 404–406. https://doi.org/10.3109/17435390.2015.1027315.
24 Germain, M., Caputo, F., Metcalfe, S. et al. (2020). Delivering the power of nanomedicine to patients today. Journal of Controlled Release 326: 164–171. https://doi.org/10.1016/j.jconrel.2020.07.007.
25 Greish, K., Mathur, A., Bakhiet, M., and Taurin, S. (2018). Nanomedicine: is it lost in translation? Therapeutic Delivery 9 (4): 1–18. https://doi.org/10.4155/tde‐2017‐0118.
26 Guadagnini, R., Kenzaoui, B.H., Walker, L. et al. (2015). Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology 9 (Suppl 1): 13–24. https://doi.org/10.3109/17435390.2013.829590.
27 Hasan, A., Morshed, M., Memic, A. et al. (2018). Nanoparticles in tissue engineering: applications, challenges and prospects. Internal Journal of Nanomedicine 13: 5637–5655. https://doi.org/10.2147/IJN.S153758.
28 Havel, H., Finch, G., Strode, P. et al. (2016). Nanomedicines: from bench to bedside and beyond. The AAPS Journal 18 (6): 1373–1378. https://doi.org/10.1208/s12248‐016‐9961‐7.
29 Heinrich, M., Martina, B., and Prakash, J. (2020). Nanomedicine strategies to target coronavirus. Nano Today 35: 1–21. https://doi.org/10.1016/j.nantod.2020.100961.
30 Jeevanandam, J., Barhoum, A., Chan, Y. et al. (2018). Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein Journal of Nanotechnology 9: 1050–1074. https://doi.org/10.3762/bjnano.9.98.
31 Juillerat‐Jeanneret, L., Dusinska, M., Fjellsbo, L. et al. (2015). Biological impact assessment of nanomaterial used in nanomedicine:
